FUNDED by the US Food
and Drug Administration (FDA)
and Pfizer, three studies have
demonstrated the ability of
Heracles Pharma’s very low nicotine
tobacco, X-22 to satisfy a smoker’s
craving for cigarettes while
separating the act of smoking from
the rapid delivery of nicotine.
The company is seeking a strategic
pharmaceutical partner to fund a
final Phase III clinical study to help
in its application to the FDA for
approval of X-22 as a prescription based
smoking cessation aid.
X-22 cigarettes have 95% less
nicotine than regular cigarettes, the
company claims.
See more at heraclespharma.com.The above article was sent to subscribers in Pharmacy Daily's issue from 26 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 May 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.